Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMC 2361951)

Published in Br J Cancer on March 28, 2005

Authors

D Roberts1, J Schick, S Conway, S Biade, P B Laub, J P Stevenson, T C Hamilton, P J O'Dwyer, S W Johnson

Author Affiliations

1: University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.

Articles citing this

STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One (2009) 1.37

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28

STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med (2009) 1.26

IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J (2013) 1.26

Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26

Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A (2014) 1.10

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics (2008) 1.04

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol (2011) 1.03

Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc (2014) 1.01

Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia (2006) 0.99

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (2009) 0.96

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS One (2013) 0.94

Tripartite motif 24 (Trim24/Tif1α) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor α (Rarα) inhibition. J Biol Chem (2011) 0.94

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer (2013) 0.93

Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. Biomaterials (2014) 0.92

Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol (2009) 0.91

The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci (2015) 0.90

Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res (2012) 0.90

Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol (2006) 0.90

Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells. Oncol Lett (2014) 0.90

Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol (2010) 0.88

Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Br J Cancer (2006) 0.87

Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer (2008) 0.86

Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res (2015) 0.84

Optical Imaging, Photodynamic Therapy and Optically Triggered Combination Treatments. Cancer J (2015) 0.84

Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther (2014) 0.81

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. Braz J Med Biol Res (2013) 0.81

Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell Death Dis (2013) 0.81

Caspase-2 short isoform interacts with membrane-associated cytoskeleton proteins to inhibit apoptosis. PLoS One (2013) 0.79

The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm (2012) 0.78

Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer. PLoS One (2014) 0.76

Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis. JAKSTAT (2015) 0.76

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Rep (2017) 0.75

Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem (2015) 0.75

Computational discovery of transcription factors associated with drug response. Pharmacogenomics J (2015) 0.75

Effect of Procyanidin-rich Extract from Natural Cocoa Powder on Cellular Viability, Cell Cycle Progression, and Chemoresistance in Human Epithelial Ovarian Carcinoma Cell Lines. Pharmacogn Mag (2016) 0.75

The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells. Cancer Inform (2008) 0.75

Articles cited by this

Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19

Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97

Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22

A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods (1989) 9.42

Jaks and STATs: biological implications. Annu Rev Immunol (1998) 7.18

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67

Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 2.44

Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene (2001) 2.25

An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res (2002) 1.82

Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res (2000) 1.68

JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol (2000) 1.45

Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett (2003) 1.42

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res (1997) 1.39

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer (1998) 1.38

New platinum complexes with anti-tumour activity. Chem Biol Interact (1972) 1.35

Substitution of chloroform by bromo-chloropropane in the single-step method of RNA isolation. Anal Biochem (1995) 1.28

Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol (2001) 1.25

Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res (2001) 1.15

Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol (2000) 1.05

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res (1997) 1.03

A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer (1993) 0.98

Recent insights into platinum drug resistance in cancer. Drug Resist Updat (1998) 0.95

Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo (1998) 0.93

Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and CDNA microarray. Head Neck (2003) 0.89

Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gan (1976) 0.87

MSSP, a protein binding to an origin of replication in the c-myc gene, interacts with a catalytic subunit of DNA polymerase alpha and stimulates its polymerase activity. FEBS Lett (2000) 0.85

Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. Cancer Genet Cytogenet (1984) 0.84

1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res (1980) 0.84

Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol (1999) 0.83

A membrane-bound Fas decoy receptor expressed by human thymocytes. J Biol Chem (2000) 0.82

Inhibitors that target protein kinases for the treatment of ovarian carcinoma. Am J Obstet Gynecol (2003) 0.78

Articles by these authors

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24

Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75

Laparoscopic versus minilaparotomy cholecystectomy: a randomised trial. Lancet (1994) 3.29

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22

Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67

Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery. Br J Surg (2006) 2.66

Surgical site infection after groin hernia repair. Br J Surg (2004) 2.54

Outcome of patients with severe chronic pain following repair of groin hernia. Br J Surg (2002) 2.38

Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24

Five-year follow-up of a randomized trial to assess pain and numbness after laparoscopic or open repair of groin hernia. Br J Surg (2004) 2.20

Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene (1999) 2.20

A case of a Spigelian hernia at an unusually high anatomical location. J R Coll Surg Edinb (2000) 2.18

Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17

Chronic groin sepsis following tension-free inguinal hernioplasty. Br J Surg (1999) 2.15

Phase I clinical trial design in cancer drug development. J Clin Oncol (2000) 2.14

Effect of a no-conversion policy on patient outcome following laparoscopic cholecystectomy. Br J Surg (1997) 2.13

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol (2004) 2.02

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer (2011) 1.99

Groin hernia repair in Scotland. Br J Surg (2000) 1.93

Bile duct injury and bile leakage in laparoscopic cholecystectomy. Br J Surg (1995) 1.87

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86

Long-term follow-up of patients with a painless inguinal hernia from a randomized clinical trial. Br J Surg (2010) 1.83

Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82

BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79

Involvement of flap endonuclease 1 in base excision DNA repair. J Biol Chem (1998) 1.73

Laparoscopic colonic resection in fast-track patients does not enhance short-term recovery after elective surgery. Colorectal Dis (2007) 1.71

Preventing complications of laparoscopy. Br J Surg (1993) 1.70

Effect of closing dead space on seroma formation after mastectomy--a prospective randomized clinical trial. Eur J Surg Oncol (1993) 1.69

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol (1996) 1.65

Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61

AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61

A randomized comparison of driver reaction time after open and endoscopic tension-free inguinal hernia repair. Surg Endosc (1999) 1.60

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58

Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55

Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol (1989) 1.52

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50

Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology (1994) 1.50

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50

Laparoscopic or minilaparotomy cholecystectomy? BMJ (1992) 1.50

Performance on the delayed word recall test (DWR) fails to differentiate clearly between depression and Alzheimer's disease in the elderly. Psychol Med (1997) 1.49

Evaluation of the long term outcome of patients with extremity desmoids. Eur J Surg Oncol (2004) 1.48

Efficacy of tumoricidal agents in vitro and in vivo. Br J Surg (1995) 1.47

Value of biopsy in the assessment of a retroperitoneal mass. Surgeon (2006) 1.47

Randomized trial of different insufflation pressures for laparoscopic cholecystectomy. Br J Surg (1997) 1.47

The biology of ovarian cancer. Semin Oncol (1998) 1.46

Symptomatic outcome 1 year after laparoscopic and minilaparotomy cholecystectomy: a randomized trial. Br J Surg (1995) 1.44

Effect of suture material on tumour cell adherence at sites of colonic injury. Br J Surg (1993) 1.43

Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res (1988) 1.42

Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol (1984) 1.41

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol (2002) 1.41

Ovarian cancer biology. Semin Oncol (1991) 1.40

HIV-related risk behaviour in UK holiday-makers. AIDS (1992) 1.40

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res (1997) 1.39

The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol (1994) 1.39

Laparoscopic and minilaparotomy cholecystectomy: a randomized trial comparing postoperative pain and pulmonary function. Surgery (1994) 1.38

Impact of video colonoscopy on stage and outcome of patients with symptomatic colorectal cancer. Surg Endosc (2004) 1.38

Randomized clinical trial comparing consultant-led or open access investigation for large bowel symptoms. Br J Surg (2003) 1.38

Hernias are the most common cause of strangulation in patients presenting with small bowel obstruction. Hernia (2006) 1.36

Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res (1984) 1.35

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer (1990) 1.35

Effect of the B-D Urine Culture Kit on an automated bacteriuria screen. J Clin Microbiol (1984) 1.35

Hormonal stimulation in the exocrine pancreas results in coordinate and anticoordinate regulation of protein synthesis. J Cell Biol (1984) 1.33

Pain from primary inguinal hernia and the effect of repair on pain. Br J Surg (2002) 1.32

The role of laparoscopic adrenalectomy for adrenal tumours of 6 cm or greater. Surg Endosc (2007) 1.31

Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro. J Physiol (2000) 1.31

Synaptic inputs to GABAA and GABAB receptors originate from discrete afferent neurons. Neurosci Lett (1992) 1.30

Cholesterol lowering diets and coronary heart disease. Dietary advice should focus on promoting antioxidants and the right sort of fats. BMJ (1998) 1.30

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28

Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol (2001) 1.28

The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res (2000) 1.27

Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res (1984) 1.25

Quantitative evidence for protein denaturation as the cause of thermal death. Nature (1971) 1.24

A noncovalent peptide complex as a model for an early folding intermediate of cytochrome c. Biochemistry (1993) 1.24

Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med (1985) 1.23

Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros (2011) 1.23

Intracellular forms of adenovirus DNA: integrated form of adenovirus DNA appears early in productive infection. Proc Natl Acad Sci U S A (1976) 1.22

Early outcome after open versus extraperitoneal endoscopic tension-free hernioplasty: a randomized clinical trial. Surgery (1996) 1.21

Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res (1996) 1.21

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol (1996) 1.21

Bacterial flagella staining. Lab Pract (1972) 1.21

GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci (2001) 1.20

The learning curve for laparoscopic hernia repair. Semin Laparosc Surg (1998) 1.18

Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res (1995) 1.18

The measurement of chronic pain and health-related quality of life following inguinal hernia repair: a review of the literature. Hernia (2008) 1.16

Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res (1994) 1.14

Diagnosis of a femoral hernia in the elective setting. J R Coll Surg Edinb (2001) 1.13

What effect does the duration of an inguinal hernia have on patient symptoms? J Am Coll Surg (2001) 1.12

Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res (1985) 1.12

Effects of urotensin II in human arteries and veins of varying caliber. Circulation (2001) 1.12